Physician profile
Ivan E Rascon-Aguilar
NPI 1750357174
$1,515.31
in general payments reported to CMS, 2019-2025
19 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $32.01 · 2021: $209 · 2022: $435 · 2023: $165 · 2024: $276 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.28 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.52 | 2019-2025 | |
| Madrigal Pharmaceuticals | $138.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $128.50 | 2019-2025 | Tremfya, Simponi, Stelara |
| Mauna Kea Technologies, INC. | $109.77 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $92.26 | 2019-2024 | Dificid |
| Celgene Corporation | $77.54 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $68.81 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.60 | 2019-2022 | |
| Teleflex LLC | $28.26 | 2024 | Solesta |
| Takeda Pharmaceuticals U.S.A., INC. | $26.16 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2024 | Dupixent |
| Amgen INC. | $19.51 | 2023 | Avsola |
| Shionogi INC | $19.05 | 2019 | |
| Axonics, INC. | $18.57 | 2024 | Axonics |
| Covidien LP | $18.23 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2022 | |
| Boston Scientific Corporation | $13.44 | 2020 | |
| Ucb, INC. | $12.65 | 2021 | |
| Qol Medical, LLC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Rascon-Aguilar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.